Maalouf G, Andrillon A, Leclercq M, Seve P, et al. Lower relapses rate with infliximab versus adalimumab in sight threatening uveitis: a multicenter study of 330 patients. Am J Ophthalmol 2022 Feb 13. pii: S0002-9394(22)00049.
PMID: 35172172